abstract |
Compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods for their synthesis, and methods of their therapeutic and/or prophylactic use are provided. Such compounds alone or in combination with incretin peptides such as GLP-1 (7-36) and GLP-1 (9-36), or peptide-based therapies such as exenatide and liraglu It may act as a modulator or potentiator of the GLP-1 receptor in combination with In the above, "(I)" represents either or both of the R and S forms of the compound; A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein. |